Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody–Positive Myasthenia Gravis

Abstract

IMPORTANCE Myasthenia gravis (MG), an autoimmune disorder of neuromuscular transmission, is treated by an array of immunotherapeutics, many of which are nonspecific. Even with current therapies, a subset of patients has medically refractory MG. The benefits of B-cell-targeted therapy with rituximab have been observed in MG; however, the duration of these benefits after treatment is unclear. OBJECTIVE To evaluate the durability of response to rituximab in the treatment of acetylcholine receptor autoantibody-positive (AChR+) generalized MG. DESIGN, SETTING AND PARTICIPANTS This retrospective case series study included 16 patients with AChR+ MG referred to an MG clinic from January 1, 2007, to December 31, 2015. The patients were treated with rituximab and followed up for 18 to 84 months after treatment. MAIN OUTCOMES AND MEASURES Assessment of long-term clinical response, durability of response and/or relapse rate, AChR autoantibody levels, adverse effects, and inflammatory markers. RESULTS In the 16 patients (6 men and 10 women; median age, 42 [range, 18-69] years), clinical improvement was observed in parallel with complete withdrawal or reduction of other immunotherapies, with all patients achieving complete stable remission, pharmacologic remission, or minimal manifestations based on the Myasthenia Gravis Foundation of America postintervention status criteria. Nine patients (56%) had a relapse during a mean follow-up of 36 (range, 24-47) months. Seven patients (44%) remained relapse free with a mean follow-up of 47 (range, 18-81) months since the last rituximab treatment. All values were normalized to a pretreatment anti-AChR antibody level of 100% and the mean levels after each rituximab cycle were calculated. A 33% decrease was seen after cycle 1 of rituximab treatment (100% vs 67%; P = .004); 20% after cycle 2 (compared with cycle 1) (67% vs 47%; P = .008); and 17% after cycle 3 (compared with cycle 2) (47% vs 30%; P = .02). However, the serum cytokine levels measured were found to be unchanged. CONCLUSIONS AND RELEVANCE Rituximab therapy appears to be an effective option in patients with refractory AChR+ MG, who were observed to have a durable response after treatment. Identification of markers of disease relapse and sustained remission are critical next steps in the development of pathophysiology-relevant, evidence-based practice parameters for rituximab in the treatment of MG.

A double‐blind, placebo‐controlled study of rituximab in patients with stiff person syndrome

“…The study demonstrated lack of efficacy of rituximab compared to placebo. In several other B-cell-mediated neurological disorders, such as multiple sclerosis, autoimmune encephalitis or myasthenia gravis, rituximab seems effective or promising 20, 25–28 . In contrast, in SPS, in spite of the presumed role of antibodies in disease pathogenesis, rituximab was not superior to placebo.…”

Low‐dose rituximab every 6 months for the treatment of acetylcholine receptor–positive refractory generalized myasthenia gravis

“…Most studies have implemented high‐dose strategies that are used in lymphoma treatment . Nevertheless, several studies have indicated that low‐dose rituximab is sufficiently potent to be effective in treating refractory MG, and a minimum of two cycles are needed to prevent potential relapses . A systematic review recommended that a repeat rituximab infusion should be considered 4 to 6 months after a cycle …”

Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis

“…Rituximab, an anti-CD20 biologic, has gained support in managing MuSK MG, as its application affects sustained clinical improvement along with a marked decline in MuSK autoantibody titer in the majority of patients (5,6). In comparison with AChR MG, fewer relapses have been reported to date in MuSK MG patients who achieved stable clinical remission after rituximab (7)(8)(9)(10)(11)(12).…”